|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||45.03 - 45.77|
|52-week range||36.60 - 58.00|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||16.05|
|Forward dividend & yield||0.87 (1.90%)|
|Ex-dividend date||26 Sep 2019|
|1y target est||46.36|
Shares of Fujifilm Holdings Corp fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials. The data reported to Japan's health ministry by hospitals treating people showing mild or no symptoms raises doubts about whether the drug can be approved by the end of this month as sought by Japan's government, the report said, citing unidentified sources. The government has not changed its plans to promptly seek approval for Avigan if its efficacy and safety can be confirmed, Chief Cabinet Secretary Yoshihide Suga said on Wednesday.
Drugs being re-purposed in hopes they will help against COVID-19 cost little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert said. "Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively," Andrew Hill, a University of Liverpool research fellow, told Reuters. In a study released Friday in the Journal of Virus Eradication, Hill and five other researchers, including Howard University chemist Joseph Fortunak, examined the cost of manufacturing medicines in recent or ongoing COVID-19 trials.
Fujifilm Holdings Corp said it has developed a new, faster test for the novel coronavirus that causes the COVID-19 disease, reducing the time of results delivery to about two hours. The test was developed by subsidiary Fujifilm Wako Pure Chemical Corp and will be released on April 15, the company said on Friday. The SARS-CoV-2 RT-qPCR detection kit will be able to test for the virus faster than existing polymerase chain reaction (PCR) tests, which take four to six hours, the company said.
TOKYO/BEIJING (Reuters) - Shares in Japan's Fujifilm Holdings Corp surged 15% on Wednesday after a Chinese official said an active ingredient of the company's Avigan anti-flu drug appeared to help coronavirus patients recover. Avigan, also known as Favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014.
FUJIFILM (FUJIY) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
These top-ranked industries stocks are witnessing positive earnings estimate revisions for 2020 and are likely to boost portfolio returns.
Here we pick six technology stocks that are well poised to generate solid returns based on strong fundamentals, an improving semiconductor space and solid prospects for the technology space.
There are chances that some of the underperforming stocks of 2019 might rebound in 2020 given the favorable factors and their fundamental strength.
Fujifilm Holdings Corp said on Tuesday it is considering buying Hitachi Ltd's diagnostic imaging business, as the Japanese photocopier and camera manufacturer aims to build up its medical business. Fujifilm has been expanding into healthcare, having recently bought a drugmaking business from U.S.-based Biogen Inc and two biotechnology units from compatriot JXTG Holdings Inc , as growth at its legacy photocopy business stagnates. Hitachi has been reorganising its business, selling non-core assets while buying foreign businesses to expand digital businesses.
MKS Instruments (MKSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Analyst Blog Highlights: Fujifilm, NXP Semiconductor, Taiwan Semiconductor Manufacturing, XILINX and Advanced Micro Devices
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.